Code of Federal Regulations (CFR), specifically 21 CFR Part 820, which governs quality system regulations and premarket submissions under 21 CFR Part 814 for devices.

European Union (EU): The In-vitro Diagnostic Regulation (IVDR 2017/746) outlines specific requirements for IVDs and their integration with medicinal products, emphasizing the role of risk classification and performance evaluation studies.

United Kingdom (MHRA): The UK Medicines and Healthcare products Regulatory Agency (MHRA) enforces regulations similar to those of the EU, with updated guidelines post-Brexit, impacting the development and commercialization of drugs and companion diagnostics.

Additionally, the International Council for Harmonisation (ICH) provides a comprehensive framework that guides good clinical practices and data submission protocols essential for regulatory approval.

Documentation

The essential documentation for aligning labeling and IFU between a drug and its companion diagnostic includes:

• Integrated Submission Dossier: A consolidated submission that incorporates both drug and diagnostics information, including clinical trial data showing drug efficacy and diagnostics accuracy.
• Labeling Submission: Clear and precise language that outlines indications, usage instructions, and contraindications relevant to the joint therapeutic use.
• Risk Management and Compliance Plan: A comprehensive overview of the risk assessment methodology undertaken to ensure that the combined product adheres to safety and efficacy standards.

Review/Approval Flow

The review and approval process for drugs and their companion diagnostics necessitate structured interaction between regulatory bodies and manufacturers. The following is a general flow of this process:

1. Pre-Submission Consultation: Engaging with the FDA, EMA, or MHRA provides early guidance on submission requirements and regulatory expectations.
2. Filing of Investigational New Drug (IND) Application: For investigational products, submissions to the FDA must include data on the companion diagnostic.
3. Concurrent Approval Strategies: Companies may choose to submit applications for concurrent approval, allowing for simultaneous review of both the drug and the diagnostic, thereby ensuring cohesiveness in labeling and IFU.
4. Post-Market Surveillance: Continuous monitoring and report submission post-approval are crucial to address any stakeholder concerns regarding the safe use of the combination products.

Common Deficiencies

Regulatory submissions are often met with queries or deficiencies. Common pitfalls include:

• Lack of Clarity in Labeling: Inconsistent or confusing language in the joint labeling can lead to misunderstandings, resulting in requests for revisions.
• Insufficient Clinical Evidence: Failing to adequately substantiate claims about drug efficacy linked to the companion diagnostic may lead to extended review periods.
• Inadequate Risk Management Strategies: Regulatory authorities expect detailed risk assessments reflecting both analytical and clinical validation of the diagnostic.

RA-Specific Decision Points

As regulatory affairs professionals navigate the complexities of drug and companion diagnostic alignment, several decision points must be made:

When to File as Variation vs. New Application

The determination of whether to file as a variation versus a new application is pivotal. A variation typically suffices when the changes involve minor adjustments to the existing product that do not alter the fundamental nature of the drug or diagnostic. Examples include:

• Updating the labeling with additional clinical data.
• Minor modifications to the manufacturing process that do not significantly affect the product’s quality or performance.

A new application is warranted when substantial changes are introduced. This may include:

• Integration of a newly developed companion diagnostic necessitating a complete re-evaluation of safety and efficacy.
• Significant changes in indications or intended use that impact the approved product scope.

Justifying Bridging Data

Bridging data may facilitate the justification of using previously established clinical evidence to support new or modified claims. To ensure appropriate justification, consider the following:

• Scientific Rationale: Provide a logical explanation that the evidence from the previous studies is still applicable.
• Demonstrating Equivalence: Use head-to-head comparisons, where applicable, to exhibit that the new drug-diagnostic pairing aligns with previously evaluated data.
• Statistical Validity: Ensure that the supporting data meet the threshold for statistical significance, reinforcing the validity of employing bridging data.

Conclusion

The regulatory landscape surrounding the alignment of labeling and IFU between drugs and companion diagnostics is intricate and is subject to rigorous scrutiny by agencies such as the FDA, EMA, and MHRA. Regulatory Affairs professionals must remain vigilant about ensuring compliance with established guidelines and addressing the myriad challenges that arise throughout the product lifecycle.

Collaboration across multidisciplinary teams, including Clinical, Quality Assurance (QA), and Commercial, is essential in circumventing deficiencies and enhancing the likelihood of successful regulatory submissions. A proactive approach to compiling comprehensive documentation, understanding agency expectations, and preparing for potential issues can significantly streamline the approval process for drug-device combinations.

For more information, refer to the detailed guidelines provided by the FDA, EMA, and MHRA regarding these products.